Cardiology

ARTESiA

Principle Investigator:
Dr Mark Williams

ARTESiA is an atrial fibrillation trial looking at people who have an Implantable Cardiac Device such as a pacemaker, ICD or loop recorder, who during their pacing appointment have been identified as having one or more episodes of AF since their last visit. The study is looking to test if an anticoagulant blood thinning drug called apixaban is superior to aspirin for prevention of stroke and systemic embolism.

Patients would randomly be assigned either Apixaban OR Aspirin and will be followed up regularly alongside pacing appointments.

SELECT

Principle Investigator:
Dr Sumeet Sharma

People with overweight or obesity are at high risk for cardiovascular (CV) disease. Semaglutide has shown CV risk reduction and impact on CV risk factors including overweight, raised glucose levels and high blood pressure in subjects with type 2 diabetes.

The SELECT trial aims to demonstrate the effect Semaglutide has on CV risk reduction and risk factors in individuals with already established CV disease and overweight or obesity.

Individuals will be randomly assigned to either 2.4mg once-weekly sub-cutaneous Semaglutide or placebo added to standard of care and followed up for a mean length of 3-4 years.

ORION-4

Principle Investigator:
Dr Peter Wilkinson

ORION-4 is a research study being coordinated by the University of Oxford and co-sponsored by The University of Oxford and The Medicines Company. The study is investigating a new medication called Inclisiran which helps to lower bad (LDL) cholesterol and aims to find out whether having an injection of Inclisiran every 6 months prevents heart attacks and strokes in individuals who have already had one of these conditions.

About 15,000 people will take part in this study across the UK. Half will get the Inclisiran injections and half will get dummy (inactive placebo) injections. Which treatment you get is randomly decided by a computer and we will not know which treatment you are given. The study is due to last approximately 5 years.

CRAFT

Principle Investigator:
Dr Zhong Chen

Cryoballoon Pulmonary Vein Isolation as first line treatment for typical atrial flutter. Patient’s with atrial flutter whom require ablation therapy will be randomized into either having conventional management by substrate removal (Cavotricuspid Isthmus (CTI) ablation) or novel management by trigger removal (no CTI ablation). Patient’s will be followed up at 3 and 12 months’ post-ablation in line with clinical care.

HORIZON

Principle Investigator:
Dr Sumeet Sharma

A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

The primary objectives of this study is to demonstrate the superiority of TQJ230 compared to placebo in reducing the risk of expanded MACE (cardiovascular death, non-fatal MI, non-fatal stroke and urgent coronary re-vascularization requiring hospitalization) in 1) the overall study population with established CVD (Lp(a) ≥ 70 mg/dL) and/or 2) in a subpopulation with established CVD and Lp(a) ≥ 90 mg/dL.

Biostream-HF - Observation of clinical routine care for heart failure patients implanted with BIOTRONIK CRT devices

Principle Investigator:
Dr Zhong Chen

The purpose of the BIO|STREAM.HF study is to gain additional knowledge about outcome, efficacy and residual safety aspects of BIOTRONIK CRT based on long-term data from a general patient population in routine care. The monitoring of these patients may help to find possible predictors for heart failure events and to identify areas of improvement for CRT and for CRT device settings.

Clear Synergy

Principle Investigator:
Dr Sumeet Sharma